Cristina Arriens to Male
This is a "connection" page, showing publications Cristina Arriens has written about Male.
Connection Strength
0.339
-
Cell-bound complement activation products associate with lupus severity in SLE. Lupus Sci Med. 2020 04; 7(1).
Score: 0.058
-
Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. Lupus Sci Med. 2020; 7(1):e000360.
Score: 0.058
-
Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017 12; 185:3-9.
Score: 0.046
-
Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus. Nutr J. 2015 Aug 18; 14:82.
Score: 0.042
-
Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases. JCI Insight. 2024 Jun 04; 9(13).
Score: 0.019
-
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021 05 29; 397(10289):2070-2080.
Score: 0.016
-
Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020 12; 146(6):1419-1433.
Score: 0.015
-
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus. Arthritis Rheumatol. 2020 01; 72(1):78-88.
Score: 0.014
-
Mock Recruitment for the Study of Antimalarials in an Incomplete Lupus Erythematosus Trial. Arthritis Care Res (Hoboken). 2019 11; 71(11):1425-1429.
Score: 0.014
-
Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis Rheumatol. 2019 03; 71(3):411-419.
Score: 0.013
-
Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial. Trials. 2018 Dec 20; 19(1):694.
Score: 0.013
-
Heightened cleavage of Axl receptor tyrosine kinase by ADAM metalloproteases may contribute to disease pathogenesis in SLE. Clin Immunol. 2016 08; 169:58-68.
Score: 0.011
-
Nonalcoholic fatty liver disease: a potential consequence of tumor necrosis factor-inhibitor therapy. Eur J Gastroenterol Hepatol. 2015 Oct; 27(10):1154-60.
Score: 0.011
-
Resistin as a potential marker of renal disease in lupus nephritis. Clin Exp Immunol. 2015 Mar; 179(3):435-43.
Score: 0.010